Probenecid Blocks Human P2X7 Receptor-Induced Dye Uptake via a Pannexin-1 Independent Mechanism by Bhaskaracharya, Archana et al.
Probenecid Blocks Human P2X7 Receptor-Induced Dye
Uptake via a Pannexin-1 Independent Mechanism
Archana Bhaskaracharya1, Phuong Dao-Ung1, Iman Jalilian2, Mari Spildrejorde2, Kristen K. Skarratt1,
Stephen J. Fuller1, Ronald Sluyter2, Leanne Stokes1,3*
1 Sydney Medical School Nepean, University of Sydney, Nepean Hospital, Penrith, New South Wales, Australia, 2 School of Biological Sciences, Illawarra Health and Medical
Research Institute, University of Wollongong, Wollongong, New South Wales, Australia, 3Health Innovations Research Institute, School of Medical Sciences, RMIT
University, Bundoora, Melbourne, Victoria, Australia
Abstract
P2X7 is a ligand-gated ion channel which is activated by ATP and displays secondary permeability characteristics. The
mechanism of development of the secondary permeability pathway is currently unclear, although a role for the
hemichannel protein pannexin-1 has been suggested. In this study we investigated the role of pannexin-1 in P2X7-induced
dye uptake and ATP-induced IL-1b secretion from human monocytes. We found no pharmacological evidence for
involvement of pannexin-1 in P2X7-mediated dye uptake in transfected HEK-293 cells with no inhibition seen for
carbenoxolone and the pannexin-1 mimetic inhibitory peptide, 10Panx1. However, we found that probenecid inhibited
P2X7-induced cationic and anionic dye uptake in stably transfected human P2X7 HEK-293 cells. An IC50 value of 203 mM was
calculated for blockade of ATP-induced responses at human P2X7. Probenecid also reduced dye uptake and IL-1b secretion
from human CD14+ monocytes whereas carbenoxolone and 10Panx1 showed no inhibitory effect. Patch clamp and calcium
indicator experiments revealed that probenecid directly blocks the human P2X7 receptor.
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Introduction
The P2X7 receptor (P2X7) is a ligand-gated ion channel
activated by extracellular ATP [1]. P2X7 activation opens an ion
channel pore allowing permeation of mono- and divalent cations
such as Na+, K+ and Ca2+. During sustained activation over a
timescale of seconds, the uptake of large organic cations (and
anions) can be measured, a feature known as secondary
permeability (reviewed in [2]). At least two distinct pathways are
thought to exist for uptake of cations and anions into macrophages
[3]. Whilst it is still not known what the physiological role of the
secondary pore pathway actually is, it is clear that signals mediated
through this pathway play an important role in P2X7 downstream
signalling. P2X7 is an important regulator of pro-inflammatory
IL-1b and interleukin 18 (IL-18) cytokine secretion from
monocytes, macrophages and microglia [4]. A mutation in the
human P2X7 receptor C-terminus which abolishes the secondary
pore pathway also impairs induction of IL-1b and IL-18
processing and secretion [5,6].
The hemichannel protein pannexin-1 was identified as contrib-
uting to the cationic dye uptake pathway induced by P2X7
activation [7]. However, several studies have brought into question
the role of pannexin-1 in the secondary permeability pathway
[3,8,9]. Schachter et al found no pharmacological evidence for
pannexin-1 in cationic dye uptake [3] and subsequently the
development of a pannexin-1 knockout mouse showed there was
no defect in P2X7-induced dye uptake in bone marrow-derived or
peritoneal macrophages [8]. Several studies had previously
demonstrated an important role for pannexin-1 in P2X7-mediated
IL-1b secretion in mouse macrophages [7,10,11]. However, Qu
et al have demonstrated no defect in IL-1b secretion from
pannexin-1 deficient macrophages [8]. Similarly there was no
defect in transient ATP-induced cell death [9]. Furthermore
Alberto et al have recently demonstrated a lack of involvement of
pannexin-1 in peritoneal murine macrophages [12] casting doubt
on the role of this protein in P2X7 mediated signalling.
We are interested in the effect of missense single nucleotide
polymorphisms (SNPs) in the human P2RX7 gene that affect the
function and downstream signalling of the ion channel. We
recently showed that a gain-of-function SNP encoding an
Ala348.Thr mutation in transmembrane domain 2 of human
P2X7 is associated with increased inward currents, dye uptake and
IL-1b secretion [13]. Our initial aim in this study was to
investigate the signalling mechanism linking P2X7 to IL-1b
secretion in human monocytes and to understand the contribution
of pannexin-1 in this process. We used a range of pharmacological
tools to investigate the role of pannexin-1 including carbenox-
olone, an inhibitory peptide to pannexin-1 (10Panx1), and
probenecid. Probenecid is also known to block organic anion
transporters [14], but recent studies have demonstrated inhibition
of pannexin-1 currents [15,16]. We found no pharmacological
evidence for pannexin-1 involvement in P2X7-mediated dye
uptake in HEK-293 cells expressing human P2X7 receptors or in
native human monocytes. Conversely probenecid reduced dye
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uptake in both HEK-293 cells and human monocytes and
suppressed ATP-induced IL-1b secretion from human monocytes.
Further investigations demonstrated that probenecid reduced
P2X7-mediated calcium responses and inward currents in stably
transfected HEK-hP2X7 cells suggesting that this compound
actually interacts with and directly blocks P2X7.
Materials and Methods
Materials
ATP, carbenoxolone and ethidium bromide were from Sigma-
Aldrich (St. Louis, MO, USA). Probenecid (water-soluble) and
lucifer yellow were from Invitrogen (Carlsbad, CA, USA).
AZ11645373, carbenoxolone, AZ10606120, 10Panx1 and scram-
bled peptides were from Tocris Biosciences (Bristol, UK).
Ethidium bromide (5 mM) and lucifer yellow (1.6 mg/ml) were
prepared in distilled water and stored at 4uC, Probenecid
(250 mM) was prepared in distilled water and stored at 230uC.
AZ11645373 (50 mM) and AZ10606120 (10 mM) were prepared
in DMSO and stocks frozen at 230uC. Carbenoxolone (50 mM)
was prepared fresh before each experiment in distilled water or
saline buffer. 10Panx1 and scrambled peptides (1 mM) were
prepared in DMSO and stored at 280uC.
Cell culture
HEK-293 cells (American Type Culture Collection, Rockville,
MD, USA) were cultured as previously described [13]. The HEK-
293 human P2X7 stable cell line (HEK-hP2X7) was maintained in
complete DMEM:F12 media containing 10% foetal bovine serum
(FBS) (Lonza Australia Pty Ltd, VIC, Australia), 100 U/ml
penicillin, 100 mg/ml streptomycin, 5 mM L-glutamine and
800 mg/ml geneticin (all Invitrogen, Carlsbad, CA, USA). Cells
were maintained at 37uC in a humidified incubator with 5% CO2.
The J774 mouse macrophage cell line (American Type Culture
Collection, Rockville, MD, USA) was maintained in RPMI-1640
medium supplemented with 10% FCS (Bovogen, East Keilor,
Australia) and 2 mM GlutaMax (Invitrogen).
Isolation of human monocytes
Peripheral venous heparinised blood was obtained from healthy
volunteers with informed written consent (approved by Nepean
Blue Mountains Local Health Network Human Ethics Committee,
10/40 – AU RED HREC/010/NEPEAN/89). Mononuclear cells
were isolated using Ficoll-Paque density gradient centrifugation.
CD14 positive monocytes were magnetically selected using CD14
microbeads and MS columns (Miltenyi Biotec, Bergisch Gladbach,
Germany) [13].
Measurement of dye uptake
Dye uptake assays on HEK-hP2X7 cells were performed using a
fluorescent plate reader (Optima FLUOSTAR, BMG Labtech).
Cells were plated the night before at a density of 56104 cells/well
in 96-well poly-D-lysine coated plates. Ethidium bromide (25 mM)
was added to low divalent solution (145 mM NaCl, 5 mM KCl,
0.2 mM CaCl2, 13 mM glucose, 10 mM HEPES, pH 7.3). Cells
were pre-incubated with drugs for 5–10 minutes at 37uC before
measurements started. ATP was injected automatically after 40
seconds. Fluorescence was measured using a 485 nm excitation
filter and a 520 nm emission filter block. Gain was set at the
beginning of the experiment to 40% required value and
fluorescence measurements were taken every 10 seconds for 300
seconds. Data was calculated as baseline corrected endpoint
measurements (at 300 seconds) and normalised as percentage of
control response.
Ethidium uptake experiments on J774 macrophages were
performed using a fixed-time assay as described previously [17]
The flow cytometer assay for ATP-induced ethidium uptake in
human monocytes was performed as previously described [13].
Briefly, 16106 peripheral blood mononuclear cells (PBMCs) were
stained with APC-conjugated CD14 antibody and FITC-conju-
gated CD3 antibody (both BD Biosciences) for 15 minutes at room
temperature. Cells were washed with PBS and resuspended in
1 ml of low divalent extracellular solution. The tube was warmed
to 37uC and 25 mM ethidium bromide added. 1 mM ATP was
added after 40 seconds and data acquired every 10 seconds for 400
seconds. Cells were acquired on a BD FACSCalibur flow
cytometer using CellQuest software (BD Biosciences, San Jose,
CA, USA). Data was calculated as area under the curve (3
minutes) as in previous studies [13].
For lucifer yellow uptake experiments, cells were plated onto
12 mm glass coverslips the day before. Cells on each coverslip
were washed briefly in standard extracellular solution (145 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 13 mM glucose,
10 mM HEPES, pH 7.3) in a 12-well plate and pre-incubated
with probenecid for 10 minutes. Lucifer yellow (LY) was prepared
to a final concentration of 0.25 mg/ml in extracellular solution.
ATP was added to a final concentration of 3 mM and cells
incubated for 15 minutes at 37uC. The coverslip was then washed
briefly in standard extracellular solution and transferred into a
heated QE-1 chamber mounted on a Nikon Ti-U Eclipse
fluorescent microscope. A phase contrast image was taken with a
Coolsnap HQ2 CCD camera (Photometrics) followed by a
fluorescent image using a 380 nm/510 nm filter block and a
fixed exposure time of 200 milliseconds. Images were analysed
using NIS Elements Advanced Research software version 3.2.
Regions of interest (ROIs) were drawn around 50-100 cells and
mean intensity calculated.
Measurement of calcium influx
Cells were loaded with 1 mM Fluo-4AM calcium indicator dye
in HBSS buffer containing zero calcium. Loading was performed
for 30 minutes at 37uC. Loading buffer was removed and replaced
with low divalent assay buffer (145 mM NaCl, 5 mM KCl,
0.2 mM CaCl2, 13 mM glucose, 10 mM HEPES, pH 7.3). Cells
were pre-incubated with drugs for 5–10 minutes at 26uC before
measurements started and ATP was injected automatically after
40 seconds. Fluorescence was measured using a 485 nm excitation
and 520 nm emission filter block. Gain was set at the beginning of
the experiment to 40% of required value and fluorescence
measurements were taken every 10 seconds.
Electrophysiology
Whole-cell patch-clamp recordings were performed at room
temperature (22–26uC) using an EPC10 amplifier and Patch-
master acquisition software (HEKA, Lambrecht, Germany).
Agonists and drugs were delivered using the RSC-160 fast-flow
system (Bio-Logic Science Instruments, France). Membrane
potential was clamped at 260 mV in all experiments. External
solution was 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 13 mM D-glucose, 10 mM HEPES, and internal solution
was 145 mM NaCl, 10 mM HEPES, 10 mM EGTA. ATP
(1 mM) was applied in low divalent solution. All solutions were
adjusted to pH 7.3 with 5 M NaOH and were 300–310 mosm/L.
IL-1b secretion assays
Magnetically purified CD14+ human monocytes were plated at
a density of 26105 cells/well (24-well plate) in RPMI 1640
medium containing 1% FCS as described in [13]. Cells were
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primed with 100 ng/ml lipopolysaccharide (LPS) for 4 hours and
then 3 mM ATP was added for 15 minutes in the presence or
absence of pharmacological agents. Cell free supernatants were
assayed for IL-1b using a paired antibody ELISA kit (BD
Biosciences).
J774 cells were plated at a density of 16106 cells/well (in 24-
well plates) in complete RPMI medium. 1000 ng/ml LPS was
used to prime the cells for 4 hours and 5 mM ATP added for 20
minutes in the presence or absence of pharmacological agents.
Cell free supernatants were assayed for IL-1b using a murine IL-
1b ELISA Max Deluxe kit (Biolegend, San Diego, CA, USA).
Statistical analysis
Data are reported as mean 6 SEM or standard deviation from
three to four separate experiments. Graphs and statistical analysis
was performed using GraphPad Prism 6 (GraphPad Software Inc.,
San Diego, CA, USA) and Student’s t-test or one-way ANOVA
were used for statistical significance where P,0.05.
Results
No evidence for pannexin-1 involvement in P2X7
receptor -induced dye uptake
We studied P2X7-induced dye uptake in HEK-293 cells using
ethidium bromide (final concentration 25 mM) and a fluorescent
plate reader. P2X7 was activated by 1 mM ATP in a low divalent
(200 mM CaCl2, zero MgCl) sodium chloride buffer. We tested a
range of drugs previously shown to act on pannexin-1 [15] –
carbenoxolone (CBX), an inhibitory peptide to pannexin-1
(10Panx) and probenecid (PRO). In HEK-293 cells stably
expressing the human P2X7 receptor (HEK-hP2X7), concentra-
tions up to 100 mM CBX had no effect on ATP-induced dye
uptake (Figure 1) whereas the selective P2X7 blockers A-438079
and AZ11645373 showed complete blockade of ATP-induced dye
uptake in HEK-293 cells at 10 mM (Figure 1B). The 10Panx1
peptide also had no effect on ATP-induced dye uptake in HEK-
hP2X7 (Figure 1). Probenecid showed a significant inhibitory
effect at 2.5 mM, reducing ATP-induced dye uptake to 4065.1%
of control (n = 5, P,0.01). Data is summarised in Figure 1B. In
contrast to HEK-hP2X7 cells, ATP-induced dye uptake was
reduced by both CBX and probenecid in J774 macrophages
(Figure 1C) and both drugs could reduce spontaneous dye uptake
in HEK-293 cells transfected with pannexin-1 (Figure S1).
Probenecid blocks P2X7-induced dye uptake in HEK-
hP2X7 cells and human monocytes
We further investigated the inhibitory effect of probenecid in
HEK-hP2X7 cells (Figure 2A) and constructed a concentration-
response curve. Probenecid blocked P2X7-mediated dye uptake
with an IC50 value of 203 mM (95% CI 138–298 mM) when using
0.2 mM ATP as agonist (Figure 2B). Raising the concentration of
ATP to 1 mM increased the IC50 value of probenecid to 1.3 mM
(95% CI 1.0–1.7 mM) (Figure 2B). A full concentration response
for the P2X7 agonist ATP was then performed in the absence and
presence of increasing concentrations of probenecid (0.5 mM,
1 mM and 5 mM) to determine if probenecid acts in a competitive
manner. A rightward shift in the dose response curve was observed
in the presence of probenecid indicating that probenecid may be a
competitive inhibitor of human P2X7 (Figure 2C). We next tested
whether probenecid would also block rat P2X7 and mouse P2X7
expressed in HEK-293 cells. Probenecid (2.5 mM) also blocked
ATP-induced dye uptake in the rat P2X7 stable cell line (34%
inhibition) and to a lesser extent in the mouse P2X7 stable cell line
(20% inhibition) (Figure 3). We then determined if this inhibitory
effect of probenecid was similar in P2X7-induced dye uptake
response in human monocytes. Probenecid (1 mM) reduced dye
uptake in human monocytes to 51% of the control ATP response
in human CD14+ monocytes (Figure 4B, n= 7 donors). As
observed for HEK-hP2X7, CBX and 10Panx1 peptide failed to
impair ATP-induced dye uptake into human monocytes whereas
the P2X7 antagonist A-438079 (10 mM) blocked dye uptake
completely in these cells (Figure S2).
To further investigate the effect of probenecid on dye uptake
induced by P2X7, we determined whether anionic dye uptake was
also inhibited by this compound. We measured ATP-induced LY
uptake in HEK-hP2X7 cells and found that probenecid could
significantly block LY uptake (Figure 5) in addition to cationic dye
uptake (Figure 1, 2). This also demonstrates that probenecid blocks
P2X7 signalling in standard extracellular solutions containing both
calcium and magnesium.
Probenecid but not CBX reduces P2X7-dependent IL-1b
secretion from monocytes
We next determined whether pannexin-1 inhibitors and
probenecid could affect P2X7-dependent IL-1b secretion from
lipopolysaccharide (LPS) primed CD14+ primary human mono-
cytes. As seen with dye uptake (Figure 4, Figure S2) CBX and
10Panx1 peptide had no effect on ATP-induced IL-1b secretion
from human monocytes (Figure 6) whereas A438079 completely
blocked ATP-induced IL-1b secretion. Figure 6A shows the effect
of CBX (50 mM), 10panx1 peptide (100 mM), A-438079 (10 mM)
and probenecid (1 mM) from a representative experiment (one
donor) and Figure 6B shows average normalised data from six
separate donors. A-438079 significantly blocked ATP-induced IL-
1b secretion to 9.968% of the ATP control, a similar level of
secretion as LPS alone (8.565.3% of ATP control, n = 6 donors).
CBX (87.766% of control) and 10Panx1 (103.169.4% of ATP
control) had no significant effect. Probenecid (1 mM) reduced
ATP-induced IL-1b secretion to 68614.6% of control (n = 6
donors, P,0.05, one-way ANOVA with Dunnett’s post-test) and a
concentration of 2.5 mM probenecid reduced ATP-induced IL-1b
secretion to 4.3% of control (n = 3 donors, P,0.05, one-way
ANOVA with Dunnett’s post-test). As previously observed by
others [7] we confirmed that CBX could impair ATP-induced IL-
1b secretion from J774 macrophages (Figure 6C). In addition, the
P2X7 antagonist AZ1061620 (10 mM) and probenecid (2.5 mM)
also showed a significant reduction in ATP-induced IL-1b
secretion (n= 3 experiments, P,0.05, one-way ANOVA with
Dunnett’s post-test).
Probenecid blocks ATP-induced calcium influx and
inward currents in HEK-hP2X7 cells
To determine if probenecid was blocking P2X7 directly as
suggested in Figure 2 we measured signalling events occurring
before pore dilation, namely channel opening. P2X7 is a non-
selective cation channel with high calcium permeability and will
induce a sustained calcium influx response to ATP. Probenecid is
widely used in loading and retaining calcium indicator dyes in the
cytoplasm of cells [18]. HEK-hP2X7 cells were loaded with Fluo-
4AM calcium indicator dye and calcium responses were recorded
at 26uC to reduce Fluo-4 extrusion through the probenecid-
inhibitable transporter. A large sustained calcium response was
measured following the addition of 1 mM ATP that was
completely blocked by the presence of 10 mM A-438079
(Figure 7A). Probenecid (1 mM) reduced this sustained calcium
response to 6365.8% of control (Figure 7A) supporting the idea
that probenecid is blocking P2X7 directly. To confirm this we
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recorded inward currents through P2X7 stably expressed in HEK-
293 cells using whole-cell patch clamp. A pulse of ATP (1 mM)
was applied for 5 seconds using a fast-flow agonist delivery system
and cells were bathed in standard extracellular saline solution
containing 1 mM probenecid for 2 minutes before re-application
of ATP. The resulting ATP-induced inward currents were
significantly reduced in presence of probenecid (Figure 7C); mean
current density to ATP was 70.967.2 pA/pF and with ATP +
probenecid 27.963.9 pA/pF (n= 5 cells, p = 0.0024, students t-
test).
Discussion
Probenecid has previously been shown to block the pannexin-1
hemichannel [15,16] in addition to inorganic anion transporters
[14,19], TASR16 [20], and unusually has agonist activity at
TRPA1 and TRPV2 channels [21,22]. It is also a commonly used
laboratory agent to enhance cellular retention of fluorescent
calcium indicator dyes [18]. Here we demonstrate for the first time
that probenecid also has a direct inhibitory effect on the human
P2X7 receptor. Our data reveal human P2X7 as another target
for probenecid and we suggest that caution be used when using
this compound to block pannexin-1 particularly in human cells.
Our data also indicates that measuring P2X7-dependent calcium
influx in buffers containing probenecid will underestimate such
responses and other methods should be used to retain indicator
dyes.
Consistent with other studies we find no pharmacological
evidence for pannexin-1 being involved in the P2X7 mediated
secondary permeability pathway [3,8,12]. There are limited
selective tools for pannexin-1; carbenoxolone (CBX) is routinely
used as a pannexin-1 antagonist in the concentration range 1–
20 mM [15] and a pannexin-1 mimetic peptide (10Panx1) [7] is
probably the most selective tool available to block pannexin-1
responses. We found no inhibitory effect on ATP-induced dye
uptake in HEK-hP2X7 cells using CBX and 10Panx1 whereas
P2X7 selective antagonists were extremely effective in blocking the
P2X7 dye uptake response (Figure 1). We also found no effect of
CBX and 10Panx1 on ATP-mediated dye uptake or IL-1b
secretion from native human monocytes (Figures 4, 6). Moreover,
we have recently observed that probenecid but not CBX blocks
ATP-mediated dye uptake in myeloid leukaemic cells [23]
Figure 1. Effect of pannexin-1 inhibitors on ATP-induced dye uptake in HEK-293 cells expressing human P2X7 and J774
macrophages. (A) Ethidium+ uptake was induced in HEK-hP2X7 expressing cells by the addition of 1 mM ATP (denoted by the arrow) in low
divalent physiological solution. Control ethidium uptake to ATP is shown in black squares. Cells were pre-incubated with inhibitors for 10 minutes at
37uC before ATP addition. In the top panel ethidium uptake in the presence of 10 mM carbenoxolone (CBX) is shown in blue circles and in the
presence of 10 mM A438079 in black open circles. In the lower panel ethidium uptakes in the presence of the pannexin-1 peptide (10Panx1) or
scrambled 10Panx1 peptide are shown in red triangles or green diamonds respectively. Cellular fluorescence was measured using a fluorescent plate
reader over 300 seconds. (B) Bar chart displaying mean data from 2–5 separate experiments using inhibitors carbenoxolone (CBX), 10Panx1 peptide or
scrambled 10panx1 peptide (100 mM), A-438079 and AZ11645373. Data was calculated at 300 second timepoint as baseline corrected endpoint data
and normalised to the ATP control. (C) ATP (3.4 mM) induced ethidium uptake was measured in J774 macrophages. CBX (50 mM), PRO (2.5 mM) and
A438079 (10 mM) significantly reduced the response. Error bars represent S.E.M, ** P,0.05 calculated by one-way ANOVA (Dunnett’s post-test).
doi:10.1371/journal.pone.0093058.g001
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however the mechanism of probenecid action was not established.
In contrast to our studies with human cells, CBX and probenecid
did reduce ATP-mediated dye uptake and IL-1b secretion in J774
mouse macrophages as previously observed [7,12] suggesting a
role for pannexin-1 in this macrophage cell line.
Probenecid was the only pannexin-1 antagonist to show marked
inhibition of ATP-induced dye uptake in our HEK-hP2X7 stable
cell line, reducing the response by 60% in our screening
experiments. We determined an IC50 value of 203 mM (95%
confidence interval 138–298 mM) blocking responses elicited by
200 mM ATP on human P2X7. Using a higher ATP concentra-
tion to stimulate P2X7 increased the IC50 value to 1.3 mM (95%
confidence interval 1.0–1.7 mM). This suggested that probenecid
may compete with ATP at the agonist binding site. Further dose
response experiments suggested that probenecid is a competitive
inhibitor of P2X7 due to the rightward shift in EC50 for the agonist
ATP (Figure 2C). The calculated IC50 value for probenecid on
human P2X7 is similar to that reported for the urate transporter
[24] and is within the therapeutic range for uricosuric activity of
probenecid (100–200 mg/ml). To further demonstrate that pro-
benecid is likely binding to P2X7 directly rather than blocking the
secondary permeability pathway (which could be mediated by
other (unknown) proteins), we measured calcium influx and
inward currents through the P2X7 ion channel. Probenecid
effectively reduced calcium influx through the P2X7 channel as
measured by the calcium indicator dye Fluo-4 and blocked inward
currents through the P2X7 channel as measured using whole cell
patch clamp (Figure 7). Therefore, probenecid can be added to a
growing list of compounds with effect at P2X7 including the
protein kinase C inhibitor chelerythrine [25], a tyrosine kinase
inhibitor [26], MAP kinase inhibitors such as SB203580 [27] and
Figure 2. Probenecid inhibits ATP-induced dye uptake in HEK-
hP2X7 cells. (A) Ethidium+ uptake was induced in HEK-hP2X7
expressing cells by the addition of 1 mM ATP (as denoted by the
arrow) in low divalent physiological solution. Control ethidium uptake
to ATP is shown in black squares and ethidium uptake in the presence
of 2.5 mM probenecid (pre-incubated for 10 minutes at 37uC) is shown
in open circles. (B) Concentration response curves for probenecid on
human P2X7 dye uptake responses induced by 0.2 mM or 1 mM ATP.
Data was calculated at 300 second timepoint as baseline corrected
endpoint data and normalised to the ATP control. Data was fit using a
normalised response variable slope in GraphPad Prism. (C) Concentra-
tion response curves for agonist ATP in the presence of increasing
concentrations of probenecid (0.5 mM, 1 mM and 5 mM) showing a
rightward shift.
doi:10.1371/journal.pone.0093058.g002
Figure 3. Probenecid shows minimal inhibition of ATP-induced
dye uptake in HEK-rat P2X7 and HEK-mouse P2X7 cells.
Ethidium+ uptake was induced in (A) rat P2X7 and (B) mouse P2X7
stable cell lines by the addition of 1 mM ATP (denoted by the arrow) in
a low divalent physiological solution. Control ethidium uptake to ATP is
shown in black squares and ethidium uptake in the presence of 2.5 mM
probenecid (pre-incubated for 10 minutes at 37uC) is shown in red
shapes.
doi:10.1371/journal.pone.0093058.g003
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the phospholipase D inhibitor CAY10593 [28]. Probenecid also
reduced spontaneous dye uptake in HEK-293 cells transfected
with pannexin-1 (Figure S1) and therefore we suggest that
probenecid can block pannexin-1 as previously demonstrated
[15,16] and additionally it can block human P2X7.
Probenecid could also block anionic dye uptake into HEK-
hP2X7 cells (Figure 5). These experiments confirm findings by
others [3] that HEK-293 cells expressing P2X7 can mediate
uptake of the anionic dye lucifer yellow in a calcium and
magnesium containing extracellular solution.
One major implication of inhibition of human P2X7 by
probenecid is the underestimation of calcium influx in fluorescent
calcium indicator dye experiments. Many protocols and kits
include probenecid at millimolar concentrations to prevent the
transporter mediated efflux of dyes such as Fluo-4 and Fura-2 out
of the cytosol during the loading period [29]. Therefore any
investigation of P2X7 responses particularly in human primary
cells or cell lines would not accurately measure P2X7-mediated
calcium influx. Alternative compounds such as sulfinpyrazone
could be used, although our preliminary experiments suggest that
this may also inhibit P2X7 responses (data not shown). Therefore
in order to measure P2X7 mediated calcium flux in human cells it
is necessary to eliminate the use of dye loading enhancers such as
probenecid. In our experience this can be achieved by loading cells
with the Fluo-4AM ester at 37uC for 30–45 minutes followed by
removal of the Fluo-4AM containing buffer. Fresh assay buffer is
added to the cells and the measurement of intracellular calcium
signals is then performed at 26uC to minimise dye extrusion. Our
experiments in Figure 7 utilised this particular protocol with
measurable P2X7 calcium responses. While the P2X7 cationic
pore pathway is known to be sensitive to changes in temperature
with reduced responses at temperatures below ambient room
temperature (20–25uC) [3], in our experiments ATP-induced
cationic dye uptake in HEK-293 cells was similar at 26uC and
37uC (data not shown).
Probenecid is a uricosuric agent clinically used to reduce serum
urate levels in the autoinflammatory arthritic disease gout [30].
Individuals with high serum uric acid levels deposit uric acid
crystals in joints which activate acute inflammatory reactions
leading to swelling and pain [31]. Studies have shown that uric
acid crystals activate the NLRP3 inflammasome in joint resident
macrophages causing pro-inflammatory cytokine secretion and
further recruitment of immune cells [32,33]. The major cytokine
implicated in the pathogenic inflammation associated with gout is
Figure 4. Probenecid inhibits P2X7-induced dye uptake in
human CD14+ monocytes. Ethidium+ uptake was induced in CD14-
APC labelled human monocytes by the addition of 1 mM ATP (denoted
by the arrow) in low divalent KCl buffer in the absence and presence of
1 mM probenecid. Dye uptake was measured on a FACSCalibur flow
cytometer using a heated time-resolved module. A representative
uptake curve is shown from 6 donors (top panel). Data (area under the
curve after 3 minutes) from all donors in shown in bottom panel scatter
plot.
doi:10.1371/journal.pone.0093058.g004
Figure 5. Probenecid blocks lucifer yellow uptake in HEK-
hP2X7 cells. Lucifer yellow (0.25 mg/ml) uptake in response to P2X7
stimulation by ATP (3 mM) was measured using a fixed time incubation
at 37uC. Coverslips were briefly washed in standard extracellular
solution before being imaged. (A) Phase contrast and fluorescent
images for each stimulation condition; Control, ATP (3 mM) and
ATP+PRO (2.5 mM) and (B) mean data from 100–300 cells (regions of
interest) from multiple images.
doi:10.1371/journal.pone.0093058.g005
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IL-1b [34]. P2X7 plays a key role in regulating activation of
NLRP3 inflammasome by the danger signal ATP and the
induction of rapid secretion of IL-1b from monocytes and
Figure 6. Probenecid but not pannexin-1 blockers reduce
P2X7-induced IL-1b secretion from humanmonocytes and J774
macrophages. Magnetically isolated CD14+ human monocytes were
primed with LPS (100 ng/ml) for 4 hours and stimulated with 3 mM ATP
for 15 minutes. After stimulation supernatants were removed and tested
for IL-1b. (A) representative data from one donor, (B) shows pooled data
from 6 donors expressed as % of ATP control. Carbenoxolone (CBX) was
used at 50 mM, probenecid (PRO) at 1 mM and 2.5 mM, 10Panx1 at
100 mM, and A-438079 at 10 mM. (C) The J774 mouse macrophage cell
line was primed with LPS (1 mg/ml) and stimulated with ATP (5 mM) for
20minutes in physiological saline. P2X7 selective antagonist AZ10606120
(AZ106) was used at 10 mM. Mean data from three independent
experiments is shown. ATP-induced IL-1b released into supernatant
was measured by specific ELISAs for human and mouse IL-1b
respectively. Error bars represent S.E.M and * represents P,0.05.
doi:10.1371/journal.pone.0093058.g006
Figure 7. Probenecid blocks P2X7-mediated calcium influx and
inward currents in HEK-hP2X7 cells. HEK-hP2X7 cells were loaded
with 1 mM Fluo-4 for 30 minutes and calcium responses recorded at
room temperature (26uC) using a fluorescent plate reader. ATP (1 mM)
was injected and fluorescence recorded at 520 nm in the absence of
inhibitors or in the presence of 1 mM probenecid (purple) or 10 mM A-
438079 (blue). (B) Mean data from three independent calcium
experiments. Sustained portion of the calcium response was measured
and calculated as % of ATP control. Probenecid reduced response to
6363.4% of control whereas A-438079 completely abolished the
sustained calcium response. (C) Inward currents through wild-type
human P2X7 receptors expressed in HEK-293 cells were recorded using
whole cell patch clamp at room temperature. Membrane was clamped
at260 mV and ATP (1 mM in low divalent solution) was applied using a
fast-flow delivery system. Black bars indicate ATP exposure (5 seconds).
The initial ATP response was measured then the cell was exposed to
probenecid for 2 minutes before re-challenge with ATP in the
continued presence of probenecid.
doi:10.1371/journal.pone.0093058.g007
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macrophages [4]. Recent studies suggest that uric acid crystals
activate the NLRP3 inflammasome by releasing ATP from
monocytes or macrophages [33,35]. Reduction of signalling
through P2X7 may be a beneficial off-target effect of probenecid
in gout. Colchicine is a second gout treatment recently shown to
block ATP-induced dye uptake in cells expressing P2X2 or P2X7
receptors [36]. Colchicine was also demonstrated to reduce ATP-
induced IL-1b secretion from macrophages [36]. Future investi-
gations into the role of P2X7 in gout may be worthwhile [37].
Supporting Information
Figure S1 CBX and PRO reduce spontaneous YO-PRO
uptake in HEK-293 cells transfected with pannexin-1.
YO-PRO iodide uptake was induced in HEK-293 cells expressing
pannexin-1 by injection of the dye (40 seconds) to a final
concentration of 5 mM. Cells were incubated in buffer alone (red),
100 mM CBX (blue) or 2.5 mM PRO (purple) for 10 minutes
before dye injection. Fluorescence was measured using a Fluostar
Optima plate reader and graph is representative of several
experiments.
(TIF)
Figure S2 Pannexin-1 antagonists have no inhibitory
effect on ATP-induced dye uptake in human monocytes.
Ethidium+ uptake was induced in CD14-APC labelled human
monocytes by the addition of 1 mM ATP (denoted by the arrow)
in low divalent KCl buffer in the absence and presence of 50 mM
CBX (blue, top panel), 100 mM 10Panx1 (red, middle panel), or
10 mM A-438079 (open circles, bottom panel). Dye uptake was
measured on a FACSCalibur flow cytometer using a heated time-
resolved module. A representative uptake curve is shown from
several donors.
(TIF)
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